Jump to navigation (n)
Jump to content
Sitemap
About us
Back
Overview
Our mission
Our team
Our history
Our investors
Our values
Community support
Social responsibility
Partnership & collaborations
Our technologies
Back
Overview
Our antibodies
Auto-regulation platform
Key capabilities
Patients & families
Back
Overview
Treatments
Patient organisations
Clinical trials
About disease areas
Pipeline
News & publications
Back
Overview
News
Publications
Careers
Back
Overview
Vacancies
Contact
Menu
Search
News
Explore
2023
2022
2021
2020
NovalGen announces data presentation at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia
Sep 17, 2021
NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
Jun 09, 2021
NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma
May 20, 2021
NovalGen receives CTA approval to start a Phase 1/2 first in human study to evaluate the safety, pharmacokinetics and efficacy of NVG-111 in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
Apr 07, 2021
NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials
Feb 22, 2021
NovalGen announces updates to its executive management team
Feb 19, 2021
Publications
Publications
Home
About us
Back
About us
About us overview
Our mission
Our team
Our history
Our investors
Our values
Community support
Social responsibility
Partnership & collaborations
Our technologies
Back
Our technologies
Our technologies overview
Our antibodies
Auto-regulation platform
Key capabilities
Patients & families
Back
Patients & families
Patients & families overview
Treatments
Patient organisations
Clinical trials
About disease areas
Pipeline
News & publications
Back
News & publications
News & publications overview
News
Publications
Careers
Back
Careers
Careers overview
Vacancies
Contact
Search